Skip to main content
SpringerLink
Log in

Invasive Fungal Infections

The Challenge Continues

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Invasive fungal infections (IFIs) are being increasingly recognized as a major threat in critically ill adult and paediatric patients. They can range widely in severity and can be life threatening in some patients. Candida and Aspergillus species are the most common causes of IFIs, but other yeasts and filamentous fungi are emerging pathogens. C. albicans, the most significant pathogenic species, is seen in almost all of the 17% of patients treated in the intensive care unit (ICU) who develop IFIs, and is associated with significant morbidity and mortality. Non-albicans spp. are becoming more common, particularly in neutropenic patients and those on existing azole therapy. Early diagnosis is challenging due to delays in, and low sensitivity of, confirmatory blood cultures, and difficulty in discriminating colonization from invasive candidiasis. Once diagnosed, early initiation of appropriate antifungal therapy is essential for reducing morbidity and mortality. Amphotericin B deoxycholate and azoles, once standard therapy, have been largely superseded in the ICU by broad-spectrum azoles, liposomal amphotericin B and the newer echinocandin agents with improved efficacy/tolerability profiles. The echinocandins (caspofungin, micafungin and anidulafungin) exhibit fungicidal activity against Candida spp. and fungistatic activity against Aspergillus spp. Echinocandins have demonstrated clinical efficacy, broad spectrum of activity and favourable pharmacological properties, and are, therefore, likely to replace fluconazole as the initial antifungal agent of choice among critically ill patients. Current evidence supports echinocandin empirical therapy for candidaemia or invasive candidiasis in ICU patients with or without neutropenia, and as rescue therapy in patients with life-threatening IFIs caused by strains resistant to other antifungals. Anidulafungin represents a new advance in the treatment of IFIs and is approved for treatment of candidaemia, intra-abdominal abscesses, peritonitis and oesophageal candidiasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995 Aug 23–30; 274(8): 639–44

    CAS  Google Scholar 

  2. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 2006 Apr; 7(4): 495–504

    Article  PubMed  CAS  Google Scholar 

  3. Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002 Apr 1; 112(5): 380–5

    Article  PubMed  Google Scholar 

  4. Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008 Oct; 21(4): 606–25

    Article  PubMed  CAS  Google Scholar 

  5. Richardson M, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008 May; 14 Suppl. 4: 5–24

    Article  Google Scholar 

  6. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002 Dec; 23(12): 759–69

    Article  PubMed  Google Scholar 

  7. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001 May 1; 32(9): 1249–72

    Article  PubMed  CAS  Google Scholar 

  8. Pittet D, Wenzel RP. Nosocomial bloodstream infections: secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995 Jun 12; 155(11): 1177–84

    Article  PubMed  CAS  Google Scholar 

  9. Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008 Jun; 112(11): 2493–9

    Article  PubMed  Google Scholar 

  10. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008 Nov; 32 Suppl. 2: S87–S91

    Article  PubMed  CAS  Google Scholar 

  11. Warnock DW. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 2007; 48(1): 1–12

    Article  Google Scholar 

  12. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003 Nov; 3(11): 685–702

    Article  PubMed  Google Scholar 

  13. Eggimann P, Pittet D. Invasive candidiasis in critically ill patients. Schweiz Med Wochenschr 2000 Oct 21; 130(42): 1525–37

    PubMed  CAS  Google Scholar 

  14. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988 Dec; 148(12): 2642–5

    Article  PubMed  CAS  Google Scholar 

  15. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992 Sep; 15(3): 414–21

    Article  PubMed  CAS  Google Scholar 

  16. Debusk CH, Daoud R, Thirumoorthi MC, et al. Candidemia: current epidemiologic characteristics and a long-term follow-up of the survivors. Scand J Infect Dis 1994; 26(6): 697–703

    Article  PubMed  CAS  Google Scholar 

  17. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002 Sep; 17(3): 168–75

    Article  PubMed  Google Scholar 

  18. Peman J, Almirante B. Advances in the diagnosis and treatment of yeast infections: role of the new antifungal agents. Enferm Infecc Microbiol Clin 2008 Nov; 26 Suppl. 13: 38–46

    Article  Google Scholar 

  19. Blot S, Dimopoulos G, Rello J, et al. Is Candida really a threat in the ICU? Curr Opin Crit Care 2008 Oct; 14(5): 600–4

    Article  PubMed  Google Scholar 

  20. Pittet D, Monod M, Filthuth I, et al. Contour-clamped homogeneous electric field gel electrophoresis as a powerful epidemiologic tool in yeast infections. Am J Med 1991 Sep 16; 91(3B): 256–63S

    Article  Google Scholar 

  21. Bassetti M, Righi E, Tamburello M, et al. Candida Infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev Anti Infrct Therapy 2006 Oct; 4(5): 875–85

    Article  CAS  Google Scholar 

  22. de Repentigny L, Reiss E. Current trends in immunodiagnosis of candidiasis and aspergillosis. Rev Infect Dis 1984 May–Jun; 6(3): 301–12

    Article  PubMed  Google Scholar 

  23. Pontòn J. Usefulness of biological markers in the diagnosis of invasive candidiasis. Rev Iberoam Micol 2009 Mar; 26(1): 8–14

    Article  PubMed  Google Scholar 

  24. Lichtenstern C, Nguyen TH, Schemmer P, et al. Efficacy of caspofungin in invasive candidiasis and candidemia: de-escalation strategy. Mycoses 2008; 51 Suppl. 1: 35–46

    Article  Google Scholar 

  25. Solomkin JS, Flohr AB, Quie PG, et al. The role of Candida in intraperitoneal infections. Surgery 1980 Oct; 88(4): 524–30

    PubMed  CAS  Google Scholar 

  26. Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther 2005 Jun; 27(6): 657–73

    Article  PubMed  CAS  Google Scholar 

  27. Mean M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008; 12(1): 204

    Article  PubMed  Google Scholar 

  28. Estes KE, Penzak SR, Calis KA, et al. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy 2009 Jan; 29(1): 17–30

    Article  PubMed  CAS  Google Scholar 

  29. Baixench MT, Aoun N, Desnos-Ollivier M, et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 2007 Jun; 59(6): 1076–83

    Article  PubMed  CAS  Google Scholar 

  30. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008 Jan; 46(1): 150–6

    CAS  Google Scholar 

  31. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections: part 2. Am J Health Syst Pharm 2006 Oct 1; 63(19): 1813–20

    Article  PubMed  CAS  Google Scholar 

  32. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections: part 1. Am J Health Syst Pharm 2006 Sep 15; 63(18): 1693–703

    Article  PubMed  CAS  Google Scholar 

  33. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004 Jun; 48(6): 2021–4

    Article  PubMed  CAS  Google Scholar 

  34. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004 Sep 15; 39(6): 770–5

    Article  PubMed  CAS  Google Scholar 

  35. Benjamin Jr DK, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006 Feb; 50(2): 632–8

    Article  PubMed  CAS  Google Scholar 

  36. Estes KE, Penzak SR, Calis KA, et al. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy 2009 Jan; 29(1): 17–30

    Article  PubMed  CAS  Google Scholar 

  37. Vehreschild JJ, Kummerle T, Karthaus M, et al. Anidulafungin: state of affairs from a clinical perspective. Mycoses 2007; 50 Suppl. 1:38–43

    Article  PubMed  CAS  Google Scholar 

  38. Montejo Gonzalez JC, Catalan Gonzalez M, Leon Gil C. Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis. Rev Iberoam Micol 2008 Jun; 25(2): 107–18

    Article  PubMed  Google Scholar 

  39. Wagner C, Graninger W, Presterl E, et al. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006; 78(4): 161–77

    Article  PubMed  CAS  Google Scholar 

  40. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007 Mar; 27(3): 369–88

    Article  PubMed  CAS  Google Scholar 

  41. Gafter-Gvili A, Vidal L, Goldberg E, et al. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008 Sep; 83(9): 1011–21

    Article  PubMed  Google Scholar 

  42. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004 Mar; 48(3): 693–715

    Article  PubMed  CAS  Google Scholar 

  43. Hof H. Developments in the epidemiology of invasive fungal infections: implications for the empiric and targeted antifungal therapy. Mycoses 2008; 51 Suppl. 1: 1–6

    Article  Google Scholar 

  44. Grigull L, Beilken A, Schmid H, et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer 2006 Jul; 14(7): 783–6

    Article  PubMed  Google Scholar 

  45. Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy 2001 Aug; 21 (8 Pt 2): 149S–64S

    Article  PubMed  CAS  Google Scholar 

  46. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979 Jul 19; 301(3): 126–31

    Article  PubMed  CAS  Google Scholar 

  47. Kulemann V, Bauer M, Graninger W, et al. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients. Pharmacology 2005 Dec; 75(4): 165–78

    Article  PubMed  CAS  Google Scholar 

  48. Munoz P, Guinea J, Narbona MT, et al. Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data. Int J Antimicrob Agents 2008 Nov; 32 Suppl. 2: S125–31

    Article  PubMed  CAS  Google Scholar 

  49. Johnson MD, Perfect JR. Combination antifungal therapy: what can and should we expect? Bone Marrow Transplant 2007 Aug; 40(4): 297–306

    Article  PubMed  CAS  Google Scholar 

  50. Oude Lashof AM, Donnelly JP, Meis JF, et al. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 2003 Jan; 22(1): 43–8

    PubMed  CAS  Google Scholar 

  51. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008 Sep 1; 47(5): 674–83

    Article  PubMed  Google Scholar 

  52. Lai CC, Tan CK, Huang YT, et al. Current challenges in the management of invasive fungal infections. J Infect Chemother 2008 Apr; 14(2): 77–85

    Article  PubMed  CAS  Google Scholar 

  53. Playford EG, Eggimann P, Calandra T. Antifungals in the ICU. Curr Opin Infect Dis 2008 Dec; 21(6): 610–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author thanks Mary Hines of Wolters Kluwer Pharma Solutions who provided assistance with English language editing. This assistance was funded by Pfizer. The author has no conflicts of interest directly relevant to the contents of this review.

Author information

Authors and Affiliations

  1. Department and School of Anesthesia and Intensive Care, Catania University-Hospital, University of Catania, Catania, Italy

    Antonino Gullo

Authors
  1. Antonino Gullo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonino Gullo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gullo, A. Invasive Fungal Infections. Drugs 69 (Suppl 1), 65–73 (2009). https://doi.org/10.2165/11315530-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11315530-000000000-00000

Keywords

Search

Navigation